Disc Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Disc Medicine (IRON).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

1S.Buy

9Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$102Upside to Avg. PT+26.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 20, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$90→$92
Oct 20, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$83→$115
Oct 20, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$86→$124
Oct 20, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$100→$110
Oct 19, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$100→$120
Oct 19, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$125→$170
Sep 16, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$79→$86
Sep 10, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$100
Sep 2, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$88→$100
Aug 6, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$118→$120
Jun 16, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$80→$85
Jun 10, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$88
May 14, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$75→$80
Mar 2, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$78→$79
Feb 27, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$114→$83
Feb 17, 2026	Stifel	Stephen Willey	PT Cut	Buy	$125→$110
Feb 17, 2026	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$153→$125
Feb 17, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$120→$100
Feb 17, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$110→$88
Feb 17, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$109→$78

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $86 to $124.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $110.

Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.

Benzinga Newsdesk

Disc Medicine Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Disc Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

PRO
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

PRO
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

PRO
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

People Also Watch

People Also Watch

Disc Medicine Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Disc Medicine Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

PROTruist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

PROWells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

PROWedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

PROBMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

PROCantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

PRO
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

PRO
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

PRO
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

PRO
BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

PRO
Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170